⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL217854 | 0.75 | — | — | |
| SCHEMBL25247012 | 0.75 | — | — | |
| SCHEMBL15769475 | 0.75 | — | — | |
| 5-Bromouracil SCHEMBL8740942 | 0.75 | — | — | |
| SCHEMBL31292534 | 0.73 | KMT2A (0.36) | — | |
| SCHEMBL4145389 | 0.71 | — | — | |
| SCHEMBL11498452 | 0.71 | — | — | |
| SCHEMBL1697670 | 0.71 | — | — | |
| SCHEMBL246368 | 0.71 | — | — | |
| SCHEMBL3576251 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884861-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884861-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170057953-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION | 2017-03-02 | — | — | US | disclosed |
| US-20170057953-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION | 2017-03-02 | — | — | US | disclosed |
| US-20170057953-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION | 2017-03-02 | — | — | US | disclosed |
| US-9334263-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2016-05-10 | — | — | US | disclosed |
| US-9334263-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2016-05-10 | — | — | US | disclosed |
| US-9334263-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2016-05-10 | — | — | US | disclosed |
| WO-2015058129-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2015-04-23 | — | — | WO | disclosed |
| US-20150111857-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2015-04-23 | — | — | US | disclosed |
| US-7288547-B2 | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2007-10-30 | — | — | US | disclosed |
| US-7288547-B2 | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2007-10-30 | — | — | US | disclosed |
| US-7288547-B2 | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2007-10-30 | — | — | US | disclosed |
| CN-1867553-A | Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2006-11-22 | — | — | CN | disclosed |
| EP-1673352-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES FOR USE AS CDK AND/OR VEGF INHIBITORS, THE PRODUCTION THEREOF AND THEIR USE AS DRUGS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-28 | — | — | EP | disclosed |
| US-20050176743-A1 | Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2005-08-11 | — | — | US | disclosed |
| WO-2005037800-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES FOR USE AS CDK AND/OR VEGF INHIBITORS, THE PRODUCTION THEREOF AND THEIR USE AS DRUGS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-28 | — | — | WO | disclosed |
| EP-1483260-A1 | CDK INHIBITING 2-HETEROARYL PYRIMIDINE, THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | Schering Aktiengesellschaft (DE) | 2004-12-08 | — | — | EP | disclosed |
| US-20040063737-A1 | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2004-04-01 | — | — | US | disclosed |
| WO-2003076437-A1 | CDK INHIBITING 2-HETEROARYL PYRIMIDINE, THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-09-18 | — | — | WO | disclosed |